Tesamorelin: Benefits, Dosage & FDA Status
Tesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
FDA Status
FDA-approved for HIV-associated lipodystrophy
Typical Dose
2 mg daily (subcutaneous)
Evidence Grade
AStrong RCT or FDA-approved evidence
Half-Life
~25 minutes
Routes of Administration
subcutaneous
First Synthesized
2005
Clinics Indexed
178 providers have offered Tesamorelin in our tracked directory.
Mechanism of Action
Stabilized 44-amino-acid GHRH analog that produces sustained, physiologic GH and IGF-1 increases.
Key Reported Benefits
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A indicates strong rct or fda-approved evidence.
Reported Side Effects
- •Injection-site reactions
- •Joint pain
- •Edema
- •Hyperglycemia
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy
- ⚠Hypothalamic-pituitary axis disruption
Commonly Stacked With
Regulatory & Safety Context
FDA status: FDA-approved for HIV-associated lipodystrophy
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Tesamorelin. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Ipamorelin
BA selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
AOD-9604
C+A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
Sermorelin
B+The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
MK-677
B+An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
GHRP-2
BA potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.